JP2020527132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527132A5 JP2020527132A5 JP2019571337A JP2019571337A JP2020527132A5 JP 2020527132 A5 JP2020527132 A5 JP 2020527132A5 JP 2019571337 A JP2019571337 A JP 2019571337A JP 2019571337 A JP2019571337 A JP 2019571337A JP 2020527132 A5 JP2020527132 A5 JP 2020527132A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- composition according
- seq
- myelin
- leukodystrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531251P | 2017-07-11 | 2017-07-11 | |
| US62/531,251 | 2017-07-11 | ||
| PCT/US2018/041636 WO2019014342A1 (en) | 2017-07-11 | 2018-07-11 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DISEASES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527132A JP2020527132A (ja) | 2020-09-03 |
| JP2020527132A5 true JP2020527132A5 (https=) | 2023-02-13 |
| JP7538602B2 JP7538602B2 (ja) | 2024-08-22 |
Family
ID=65001812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571337A Active JP7538602B2 (ja) | 2017-07-11 | 2018-07-11 | ミエリン障害を治療するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200230205A1 (https=) |
| EP (1) | EP3651785B1 (https=) |
| JP (1) | JP7538602B2 (https=) |
| KR (1) | KR102772298B1 (https=) |
| CN (1) | CN111093684A (https=) |
| AU (2) | AU2018301399B2 (https=) |
| CA (1) | CA3064463A1 (https=) |
| ES (1) | ES3056700T3 (https=) |
| WO (1) | WO2019014342A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240167030A1 (en) * | 2021-04-02 | 2024-05-23 | Case Western Reserve University | Methods and compositions for accelerating oligodendrocyte maturation |
| WO2025092748A1 (zh) * | 2023-11-01 | 2025-05-08 | 拜西欧斯（北京）生物技术有限公司 | 多肽衍生物、其药物组合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4731058A (en) | 1986-05-22 | 1988-03-15 | Pharmacia Deltec, Inc. | Drug delivery system |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5368562A (en) | 1993-07-30 | 1994-11-29 | Pharmacia Deltec, Inc. | Systems and methods for operating ambulatory medical devices such as drug delivery devices |
| GB9718609D0 (en) | 1997-09-02 | 1997-11-05 | Imp College Innovations Ltd | Fusion protein |
| US6841535B2 (en) | 2000-07-31 | 2005-01-11 | Active Motif | Peptide-mediated transfection agents and methods of use |
| SI1931660T1 (sl) * | 2005-09-29 | 2012-12-31 | Sanofi | Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila |
| CA3233345A1 (en) * | 2012-04-09 | 2013-10-17 | Case Western Reserve University | Compositions and methods for inhibiting the activity of lar family phosphatases |
| US10258672B2 (en) * | 2014-10-09 | 2019-04-16 | Case Western Reserve University | Compositions and methods of treating root avulsion injury |
-
2018
- 2018-07-11 KR KR1020197037688A patent/KR102772298B1/ko active Active
- 2018-07-11 US US16/630,271 patent/US20200230205A1/en active Pending
- 2018-07-11 JP JP2019571337A patent/JP7538602B2/ja active Active
- 2018-07-11 CN CN201880042147.3A patent/CN111093684A/zh active Pending
- 2018-07-11 AU AU2018301399A patent/AU2018301399B2/en active Active
- 2018-07-11 EP EP18832119.4A patent/EP3651785B1/en active Active
- 2018-07-11 WO PCT/US2018/041636 patent/WO2019014342A1/en not_active Ceased
- 2018-07-11 CA CA3064463A patent/CA3064463A1/en active Pending
- 2018-07-11 ES ES18832119T patent/ES3056700T3/es active Active
-
2024
- 2024-11-25 AU AU2024266863A patent/AU2024266863A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rook et al. | Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic: ME Rook et al. | |
| Lazdon et al. | Microglia and Parkinson's disease: footprints to pathology | |
| Lindvall et al. | Stem cells in human neurodegenerative disorders—time for clinical translation? | |
| Govoni et al. | Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy | |
| Gerards et al. | Leigh syndrome: resolving the clinical and genetic heterogeneity paves the way for treatment options | |
| Collier et al. | Therapeutic potential of nerve growth factors in Parkinson’s disease | |
| US6776984B1 (en) | Induced regeneration and repair of damaged neurons and nerve axon myelin | |
| Nagahara et al. | Potential therapeutic uses of BDNF in neurological and psychiatric disorders | |
| Suksuphew et al. | Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases | |
| Bebee et al. | Mouse models of SMA: tools for disease characterization and therapeutic development | |
| JP2016517884A5 (https=) | ||
| Wallom et al. | Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease | |
| Alam et al. | New insights into the role of fibroblast growth factors in Alzheimer’s disease | |
| JP2020527132A5 (https=) | ||
| HRP20151409T1 (hr) | Lijeäśenje sinukleinopatija | |
| JP2018531965A5 (https=) | ||
| Rodrigues et al. | Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson’s disease | |
| Vanhoof‐Villalba et al. | Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy | |
| Zuccaro et al. | Motor neuron diseases and neuroprotective peptides: a closer look to neurons | |
| Zhang et al. | Neuritin inhibits astrogliosis to ameliorate diabetic cognitive dysfunction | |
| JP2021534206A5 (https=) | ||
| Ho | Clearance pathways for α‐synuclein in Parkinson's disease | |
| JP2021532155A5 (https=) | ||
| JP2012522005A (ja) | 神経損傷および神経変性疾患後の神経学的転帰を改善する方法 | |
| WO2008057609A4 (en) | Methods of treating neuronal disorders using mntf peptides and analogs thereof |